John L. Brooks
Independent ChairmanMr. John L. Brooks, III, MSBA, CPA, BBA, is an Advisor of KeborMed Inc. He serves as Member of Advisory Board at Carna Inc. He is Chief Strategy Officer of Carna Inc. He is Independent Director at Sharp Therapeutics Corp. since December 11, 2024. He serves as Independent Chairman since September 22, 2025 at Sernova Biotherapeutics Inc. He served as Chief Commercial Officer & Board Member of Basys.ai Inc until 2025. Mr. Brooks is President and CEO of Diamune, Inc. He serves as the Director of Hemoshear Therapeutics Inc. Mr. Brooks serves as Member of Business Advisory Board at BioSurfaces, LLC. He serves as Director at Alertgy since 2023, sharp Tx since 2023. He serves as Director at Altrixbio, Inc since December 2021. He serves as Advisor of General Prognostics, Inc. He serves as Director of T1D Exchange, Inc. since May 2020. He was President of Nutritech Therapeutics Division at L-Nutra Inc. since September 2021 until May 2022. He served as an Independent Director of iSpecimen Inc. since June 21, 2021 until June 18, 2025. He is Executive Advisor at GrayBella Capital. Mr. Brooks has been Member of Advisory Board at QSM Diagnostics, Inc. since 2020. He serves as the President and Chief Executive Officer of Arete Worldwide, LLC. He served as the President, Director and Chief Executive Officer of NeuroBo Pharmaceuticals, Inc since March 2018 until December 30, 2019. Mr. Brooks serves as the Founder, Principal and Consultant of Healthcare Capital Consulting LLC, offering consultation services to early-stage companies. He is also a co-founder of Rocky Mountain Biphasic and serves as a director since April 2022. He serves as the President and Managing Director at Healthcare Capital, LLC. He is a Venture Partner and Member of the Board of Directors at Pittsburgh Life Sciences Greenhouse. He served as a Senior Advisor at Johnston Blakely & Company, LLC until 2011. He serves as a Senior Advisor at TVM Capital Healthcare Partners. At TVM, he works alongside the firm's investment and operations teams to identify new investment opportunities. Mr. Brooks serves as an Advisor of PureTech Health PLC. He serves as an Advisor for the Massachusetts Technology Transfer Center. He co-founded Prism Venture Management, LLC in 1996 and served as its General Partner. He was a valued member of the life sciences team in Prism. Consistent with Prism's role as the entrepreneur's venture capitalist, he actively worked with its healthcare companies to grow successful businesses by evaluating the myriad of issues facing early and growth-stage companies. From 2009 to 2015, he also served as the Chairman and Chief Executive Officer of Reflectance Medical, Inc. He serves as Chairman of board at Thermalin Diabetes, LLC (insulin technology. He served as the Chief Executive Officer and President of Joslin Diabetes Center, Inc. from April 2011 to September 10, 2015. He served as the President and Managing Director at Medical Capital Advisors. He served as the President of Pfizer/Strato Medical where he had also served as Vice President of Finance. Previously, he served as a General Manager at Pfizer/Valleylab, where he developed and executed a comprehensive, minimally invasive surgery strategy and responsible for Pfizer's Hospital Products Group's minimally invasive surgery and new medical technologies business. With Pfizer/Strato, he led the growth of a rapidly evolving vascular access medical device business. He also held several Vice President of Finance and Operations positions at successful high-tech, venture-backed companies and spent in public accounting and consulting focused on supporting venture-backed entrepreneurs. He co-founded five life science companies including Songbird Hearing, Locus Pharmaceuticals and Insulet Corporation. He joined Medical Capital Advisors in February 2008 and played a key role in its development. He has wealth of strategic, clinical, operational and financial experience to his client companies. His operational knowledge of regulatory, reimbursement, clinical adoption, marketing and distribution issues make him a particular asset in the life sciences industry. He had been the Chairman and Director of Cellnovo Group SA (formerly known as Cellnovo Limited) (diabetes management system) from 2012 to December 2019. He is the Chairman of College Diabetes Network (diabetes-focused non-profit). He also serves a Board Member of Ammonett Pharma. Mr. Brooks has been a Director of Hygieia, Inc. since June 08, 2016 and Pathfinder Cell Therapy, Inc. since September 2011. He serves as a Director of OptiScan Biomedical, HemoShear Therapeutics, LLC, Confirma and MedManage Systems. Mr. Brooks served as Scientific Advisory Board Member of Xeris Pharmaceuticals, Inc. He serves on the Scientific Advisory Board of Valley of Life & T1D Innovations. He has co-founded seven life science companies, including Insulet. He was a founding managing partner of Prism Venture Partners. Mr. Brooks is a Biotechnology Advisory Board Member for Draper Labs. He serves as a Board Member of Mass Medic's Ignite entrepreneurial center as well as the CIMIT and MTTC advisory boards. He served as a Advisory Board Member of LifePod Solutions, Inc. until April 2020. Mr. Brooks serves as a Member of the Board of Associates for the Whitehead Institute. He served as the Chairman of the Board at Joslin Diabetes Center, Inc. from May 2010 to April 2011. He served as the Chairman of OmniSonics Medical Technologies, Inc until September 2007 and served as its Director. He served as the Chairman and Director of Merge CAD Inc. and Veraxa Health Inc. He served as Vice Chairman of Joslin Diabetes Center, Inc. He served as a director of Noxilizer, Inc. until September 2025. Mr. Brooks served as a Board Member at Quorex Pharmaceuticals, Inc. Spotlight Health, Inc. Cortek, Inc. Uptake Medical Corp, Peptimmune, Inc and Percardia, Inc. He served as a Trustee of Joslin Diabetes Center, Inc until September 10, 2015. He serves as a director of Atentiv since March 2020. He currently serves as the Chief Executive Officer and President of Worldwide Network for Innovation in Clinical Education and Research (WNICER) since January 2019 and serves as a director of T1D Exchange since March 2020, the ADA New England Chapter since January 2015, Population Health Alliance since January 2014 and the University of Massachusetts Amherst Foundation since January 2012. He serves as Trustee at Suffolk University. He serves as Member of Strategic Advisory Board at Senscio Systems, Inc. He serves as Director at The Diabetes Link since January 2010. He was Industry Advisor at LRVHealth from September 2018. He served as a senior manager at Arthur Anderson & Co and serves on the boards of various diabetes and population health organizations. He is also a board Member of Sharp Therapeutics. Mr. Brooks is a Certified Public Accountant and a Certified Financial Planner. He holds an M.S. in Business Administration and a BBA cum laude in Computer Science and Acc
Positions
- Company NameSernova Biotherapeutics IncStock CodeSEOVFPositionIndependent ChairmanColleagues
- JMJonathan M. N. RigbyPresident, CEO & Director
- JTJames T. ParsonsChief Financial Officer
- MRMarylyn RigbyChief Communications Officer
- DBDavid BurkeVice President of Investor Relations
- PBPatricia BeastonSernova Biotherapeutics Inc.
- RARobert A. GabbayChairman of Clinical Advisory Board
- NCNorman C. W. WongMember of Scientific Advisory Board
- JDJannette DufourMember of Scientific Advisory Board
